These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 19616605)

  • 21. Triple-negative/basal-like breast cancer: clinical, pathologic and molecular features.
    Venkitaraman R
    Expert Rev Anticancer Ther; 2010 Feb; 10(2):199-207. PubMed ID: 20131996
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinicopathological characteristics of triple-negative breast cancers.
    Sasaki Y; Tsuda H
    Breast Cancer; 2009; 16(4):254-9. PubMed ID: 19657711
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Indicators of homologous recombination deficiency in breast cancer and association with response to neoadjuvant chemotherapy.
    Lips EH; Mulder L; Hannemann J; Laddach N; Vrancken Peeters MTFD; van de Vijver MJ; Wesseling J; Nederlof PM; Rodenhuis S
    Ann Oncol; 2011 Apr; 22(4):870-876. PubMed ID: 20937646
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Contemplating chemosensitivity of basal-like breast cancer based on BRCA1 dysfunction.
    Ohta T; Wu W; Koike A; Asakawa H; Koizumi H; Fukuda M
    Breast Cancer; 2009; 16(4):268-74. PubMed ID: 19459031
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Triple positive breast cancer: a distinct subtype?
    Vici P; Pizzuti L; Natoli C; Gamucci T; Di Lauro L; Barba M; Sergi D; Botti C; Michelotti A; Moscetti L; Mariani L; Izzo F; D'Onofrio L; Sperduti I; Conti F; Rossi V; Cassano A; Maugeri-Saccà M; Mottolese M; Marchetti P
    Cancer Treat Rev; 2015 Feb; 41(2):69-76. PubMed ID: 25554445
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacotherapy of triple-negative breast cancer.
    Arslan C; Dizdar O; Altundag K
    Expert Opin Pharmacother; 2009 Sep; 10(13):2081-93. PubMed ID: 19640211
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Triple-negative breast cancer: epidemiology and management options.
    Dawood S
    Drugs; 2010 Dec; 70(17):2247-58. PubMed ID: 21080741
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Breast tumor immunophenotype of BRCA1-mutation carriers is influenced by age at diagnosis.
    Vaziri SA; Krumroy LM; Elson P; Budd GT; Darlington G; Myles J; Tubbs RR; Casey G
    Clin Cancer Res; 2001 Jul; 7(7):1937-45. PubMed ID: 11448907
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinicopathological features and treatment strategy for triple-negative breast cancer.
    Yamamoto Y; Iwase H
    Int J Clin Oncol; 2010 Aug; 15(4):341-51. PubMed ID: 20632057
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Biology, metastatic patterns, and treatment of patients with triple-negative breast cancer.
    Anders CK; Carey LA
    Clin Breast Cancer; 2009 Jun; 9 Suppl 2(Suppl 2):S73-81. PubMed ID: 19596646
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer.
    Haffty BG; Yang Q; Reiss M; Kearney T; Higgins SA; Weidhaas J; Harris L; Hait W; Toppmeyer D
    J Clin Oncol; 2006 Dec; 24(36):5652-7. PubMed ID: 17116942
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Microcephalin is a new novel prognostic indicator in breast cancer associated with BRCA1 inactivation.
    Richardson J; Shaaban AM; Kamal M; Alisary R; Walker C; Ellis IO; Speirs V; Green AR; Bell SM
    Breast Cancer Res Treat; 2011 Jun; 127(3):639-48. PubMed ID: 20632086
    [TBL] [Abstract][Full Text] [Related]  

  • 33. alphaB-crystallin is a novel predictor of resistance to neoadjuvant chemotherapy in breast cancer.
    Ivanov O; Chen F; Wiley EL; Keswani A; Diaz LK; Memmel HC; Rademaker A; Gradishar WJ; Morrow M; Khan SA; Cryns VL
    Breast Cancer Res Treat; 2008 Oct; 111(3):411-7. PubMed ID: 17968656
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Breast cancers with compromised DNA repair exhibit selective sensitivity to elesclomol.
    Alli E; Ford JM
    DNA Repair (Amst); 2012 May; 11(5):522-4. PubMed ID: 22425348
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [PARP inhibitors and their role in the therapy of triple-negative metastatic breast cancer].
    Kozioł M; Püsküllüoglu M; Zygulska A
    Przegl Lek; 2012; 69(6):265-70. PubMed ID: 23094440
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Possible treatment strategies for triple-negative breast cancer on the basis of molecular characteristics.
    Kurebayashi J
    Breast Cancer; 2009; 16(4):275-80. PubMed ID: 19408071
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Insights into biology of luminal HER2 vs. enriched HER2 subtypes: Therapeutic implications.
    Harbeck N
    Breast; 2015 Nov; 24 Suppl 2():S44-8. PubMed ID: 26321480
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Molecular profiling of triple negative breast cancer.
    Ma CX; Luo J; Ellis MJ
    Breast Dis; 2010; 32(1-2):73-84. PubMed ID: 21778575
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Numb protein expression correlates with a basal-like phenotype and cancer stem cell markers in primary breast cancer.
    Rennstam K; McMichael N; Berglund P; Honeth G; Hegardt C; Rydén L; Luts L; Bendahl PO; Hedenfalk I
    Breast Cancer Res Treat; 2010 Jul; 122(2):315-24. PubMed ID: 19795205
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical implications of the intrinsic molecular subtypes of breast cancer.
    Prat A; Pineda E; Adamo B; Galván P; Fernández A; Gaba L; Díez M; Viladot M; Arance A; Muñoz M
    Breast; 2015 Nov; 24 Suppl 2():S26-35. PubMed ID: 26253814
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.